Bone Health Observational Study

A consequence of ADT is the gradual bone loss, so-called cancer treatment induced bone loss (CTIBL). The current standard of care is the addition of Vitamin D and Calcium upon the initiation of ADT. Moreover, bisphosphonates are now being considered to treat and prevent CTIBL. However, bisphosphonates are costly, thus there is a desire to identify or target a specific subset of patients who would most benefit from the treatment.

By obtaining baseline BMD and monitoring for Skeletal Related Events (SREs), we hope to identify that specific sub-set of patients who would most benefit from the treatment. Using a prospective, observational study design, we propose monitoring how physicians manage CTIBL in their patients.

Inclusion criteria

• Patients willing to provide written Informed Consent.
• Patients for whom Androgen Deprivation Therapy (ADT) with Zoladex® is indicated for at least 1 year.
• Patients started on Zoladex® within the last 4 months.

Exclusion criteria

• Patient had surgery or significant traumatic injury occurring within 1 month prior to consent.
• Known hypersensitivity to Goserelin Acetate or any of the components found in Zoladex®.
• Any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.